PCOS&DUB的中医证候特征及中西医结合治疗
|
摘要
目的：
通过聚类分析的方法,归纳PCOS&DUB的证型特征,通过随机对照法对所收集的病例进行分组,运用中西医结合的方法对治疗组进行治疗,通过与对照组对照,验证中西医结合的治疗方案对治疗PCOS&DUB的安全性和有效性,以期为临床治疗PCOS&DUB提供指导。
方法：
1.根据PCOS&DUB诊断标准,结合中医望、闻、问、切四诊方法,收集临床资料,建立数据库,运用聚类分析的方法,对所收集的资料进行聚类分析,归纳PCOS&DUB证型特征,分析其病因病机,制定其治疗原则,以期望为临床治疗提供指导。
2.对所收集的临床病例随机分为治疗组和对照组,治疗组在不规则出血期服止血方10剂；地屈孕酮片1盒,于撤退性出血第5天起开始服助卵调经方14剂,下次月经周期第5天开始继续服助卵调经方14剂,连续3个月经周期。对胰岛素抵抗及高胰岛素血症患者予胰岛素增敏剂盐酸二甲双胍片及盐酸吡格列酮口腔崩解片3个月经周期。同时指导患者三高三低饮食(高蛋白、高纤维、高微量元素及低糖、低脂、低盐)及非出血期有氧运动。对照组选用去氧孕烯炔雌醇片止血、调经治疗3个月经周期。
结果：
通过对比发现,治疗组和对照组在中医症候疗效、治疗后中医症状积分、对照组治疗前后血红蛋白含量、治疗后血红蛋白含量、对照组治疗前后BMI、治疗组治疗前后BMI、对照组治疗前后WHR、治疗组治疗前后WHR、治疗组中肾虚痰阻组、脾虚湿困组及肾虚血瘀组半年后复发情况与对照组比较均有显著性差异(P<0.05)。对照组治疗前后中医症状积分、治疗组治疗前后中医症状积分、治疗组治疗前后血红蛋白含量比较均有极显著性差异(P<0.01)。治疗组和对照组临床总疗效、治疗组与对照组治疗后BMI、治疗组与对照组治疗后WHR比较、治疗组和对照组阴道流血的血止时间、治疗组和对照组调整月经周期疗效、治疗组和对照组治疗后B超疗效比较均无显著性差异(P>0.05)。
结论：
通过对比发现本中西医结合治疗方案是治疗PCOS&DUB行之有效的安全、综合方案,在控制患者不规则出血、调整月经周期、防止复发等方面疗效显著,可以在临床推广实施。
Objective:
By the methods of Clustering analysis to inductive the evidence type characteristics of PCOS&DUB; Through the randomized controlled method to group the collected cases; Verify the safety and effectiveness of the treatment plans of Combine traditional Chinese and western medicine which treatment PCOS&DUB by the comparison with the control, in order to provide guidance for clinical treatment PCOS&DUB.
Methods:
1. According to the diagnosis standard of PCOS&DUB, combined with four diagnostic methods of TCM' inspection, Listening and smelling, inquiry and pulse feeling to collect Clinical data and set up the database; Inductive card type of PCOS&DUB and analysis of the etiology and pathogenesis; Formulate the treatment principle and to provide guidance for clinical treatment.
2. To collect clinical cases randomly divided into treatment group and control group, the control group take10prescriptions for medicine of hemostatic, Dydrogesterone1box, Began to take14prescriptions for helping ovum and regulating menstruation in the fifth day retreat hemorrhages. Began to take14prescriptions for helping ovum and regulating menstruation in the fifth day of the next menstrual cycle and for three consecutive menstrual cycle. For patients with insulin resistance and hyperinsulinemia.To give metformin hydrochloride and Pioglitazone hydrochloride of insulin sensitizer for three menstrual cycles. At the same time to guide the patients with three high three low diet(High protein, high fiber, high trace elements and low sugar, low fat, and low salt),and do aerobic exercise in unbleeding during.Control group choose desogestrel ethinylestradiol slices to treatment hemostatic, regulate the menstrual function for three menstrual cycles.
Results:
The treatment group and control group had significant difference by comparing the found,which in TCM'Symptom curative effect, after treatment of TCM'symptom integral, the hemoglobin levels of the control group before and after treatment, the hemoglobin levels after treatment of the control group, the BMI of treatment group before and after treatment, the WHR of control group before and after the treatment, the WHR of treatment group before and after the treatment, the group of deficiency of the kidney and stagnation of phlegm in the treatment group, Recurrence of the group of spleen deficient and wet trapped and the group of deficiency of the kidney and blood stasis after half a year compared with the control group had significant difference (P<0.05). The TCM' symptom integral of the control group before and after treatment, The TCM' symptom integral of treatment group before and after treatment, the hemoglobin content comparison before and after the treatment are very significant differences in treatment group (P<0.01). The treatment group and control group had no significant difference in total clinical curative effect, BMI after treatment, WHR comparison after treatment, stop bleeding time of vaginal bleeding, adjust the menstrual cycle, curative effect comparison of ultrasound after treatment (P>0.05)
Conclusion:
By comparing we can found that the treatment plan of TCM and western medicine for treating the PCOS&DUB is effective security, comprehensive solution.The curative effect is distinct in controlling irregular bleeding, adjust the menstrual cycle and preventing relapse.
通过聚类分析的方法,归纳PCOS&DUB的证型特征,通过随机对照法对所收集的病例进行分组,运用中西医结合的方法对治疗组进行治疗,通过与对照组对照,验证中西医结合的治疗方案对治疗PCOS&DUB的安全性和有效性,以期为临床治疗PCOS&DUB提供指导。
方法：
1.根据PCOS&DUB诊断标准,结合中医望、闻、问、切四诊方法,收集临床资料,建立数据库,运用聚类分析的方法,对所收集的资料进行聚类分析,归纳PCOS&DUB证型特征,分析其病因病机,制定其治疗原则,以期望为临床治疗提供指导。
2.对所收集的临床病例随机分为治疗组和对照组,治疗组在不规则出血期服止血方10剂；地屈孕酮片1盒,于撤退性出血第5天起开始服助卵调经方14剂,下次月经周期第5天开始继续服助卵调经方14剂,连续3个月经周期。对胰岛素抵抗及高胰岛素血症患者予胰岛素增敏剂盐酸二甲双胍片及盐酸吡格列酮口腔崩解片3个月经周期。同时指导患者三高三低饮食(高蛋白、高纤维、高微量元素及低糖、低脂、低盐)及非出血期有氧运动。对照组选用去氧孕烯炔雌醇片止血、调经治疗3个月经周期。
结果：
通过对比发现,治疗组和对照组在中医症候疗效、治疗后中医症状积分、对照组治疗前后血红蛋白含量、治疗后血红蛋白含量、对照组治疗前后BMI、治疗组治疗前后BMI、对照组治疗前后WHR、治疗组治疗前后WHR、治疗组中肾虚痰阻组、脾虚湿困组及肾虚血瘀组半年后复发情况与对照组比较均有显著性差异(P<0.05)。对照组治疗前后中医症状积分、治疗组治疗前后中医症状积分、治疗组治疗前后血红蛋白含量比较均有极显著性差异(P<0.01)。治疗组和对照组临床总疗效、治疗组与对照组治疗后BMI、治疗组与对照组治疗后WHR比较、治疗组和对照组阴道流血的血止时间、治疗组和对照组调整月经周期疗效、治疗组和对照组治疗后B超疗效比较均无显著性差异(P>0.05)。
结论：
通过对比发现本中西医结合治疗方案是治疗PCOS&DUB行之有效的安全、综合方案,在控制患者不规则出血、调整月经周期、防止复发等方面疗效显著,可以在临床推广实施。
Objective:
By the methods of Clustering analysis to inductive the evidence type characteristics of PCOS&DUB; Through the randomized controlled method to group the collected cases; Verify the safety and effectiveness of the treatment plans of Combine traditional Chinese and western medicine which treatment PCOS&DUB by the comparison with the control, in order to provide guidance for clinical treatment PCOS&DUB.
Methods:
1. According to the diagnosis standard of PCOS&DUB, combined with four diagnostic methods of TCM' inspection, Listening and smelling, inquiry and pulse feeling to collect Clinical data and set up the database; Inductive card type of PCOS&DUB and analysis of the etiology and pathogenesis; Formulate the treatment principle and to provide guidance for clinical treatment.
2. To collect clinical cases randomly divided into treatment group and control group, the control group take10prescriptions for medicine of hemostatic, Dydrogesterone1box, Began to take14prescriptions for helping ovum and regulating menstruation in the fifth day retreat hemorrhages. Began to take14prescriptions for helping ovum and regulating menstruation in the fifth day of the next menstrual cycle and for three consecutive menstrual cycle. For patients with insulin resistance and hyperinsulinemia.To give metformin hydrochloride and Pioglitazone hydrochloride of insulin sensitizer for three menstrual cycles. At the same time to guide the patients with three high three low diet(High protein, high fiber, high trace elements and low sugar, low fat, and low salt),and do aerobic exercise in unbleeding during.Control group choose desogestrel ethinylestradiol slices to treatment hemostatic, regulate the menstrual function for three menstrual cycles.
Results:
The treatment group and control group had significant difference by comparing the found,which in TCM'Symptom curative effect, after treatment of TCM'symptom integral, the hemoglobin levels of the control group before and after treatment, the hemoglobin levels after treatment of the control group, the BMI of treatment group before and after treatment, the WHR of control group before and after the treatment, the WHR of treatment group before and after the treatment, the group of deficiency of the kidney and stagnation of phlegm in the treatment group, Recurrence of the group of spleen deficient and wet trapped and the group of deficiency of the kidney and blood stasis after half a year compared with the control group had significant difference (P<0.05). The TCM' symptom integral of the control group before and after treatment, The TCM' symptom integral of treatment group before and after treatment, the hemoglobin content comparison before and after the treatment are very significant differences in treatment group (P<0.01). The treatment group and control group had no significant difference in total clinical curative effect, BMI after treatment, WHR comparison after treatment, stop bleeding time of vaginal bleeding, adjust the menstrual cycle, curative effect comparison of ultrasound after treatment (P>0.05)
Conclusion:
By comparing we can found that the treatment plan of TCM and western medicine for treating the PCOS&DUB is effective security, comprehensive solution.The curative effect is distinct in controlling irregular bleeding, adjust the menstrual cycle and preventing relapse.
引文
[1]group, The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)[J].Human Reproduction,2004,19(1):41-47.
[2]刘敏如、谭万信.中医妇产科学[M].北京：人民卫生出版社,2001：307.
[3]王永炎.完善中医辨证方法体系的建议[J].中医杂志,2004,45(10)：729-731.
[4]中医药管理局.《中华人民共和国中医药行业标准·中医病证诊断疗效标准》[M].北京,1994.
[5]中华人民共和国卫生部.《中药新药临床研究指导原则》[M].北京,1993.
[6]张玉珍.《中医妇科学》[M].北京：中国中医药出版社,2007.
[7]中国中西医结合研究会第一次全国活血化瘀学术会议：血瘀证诊断试行标准.中西医结合杂志,1983：3(3)：封二.
[8]王桂敏,郑淑荣.女性生殖器官血管研究现状.生殖与避孕,1996,1(1)：3-6.
[9]胡淑芳.经阴道彩色多普勒观测卵巢动脉PI、RI值和卵泡发育的关系.临床超声医学杂志,1995,1(4)：215-218.
[10]陈可冀,张子南,梁子均等.血瘀证与活血化瘀研究.上海：上海科学技术出版社,1990.368.
[11]郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002.
[12]罗璐.功能失调性子宫出血研究新进展[M].国外医学妇产科学分册,2002,29(2)：88.
[13]邢小燕,杨文英,杨兆军.胰岛素抵抗指数在不同糖耐量人群中诊断代谢综合征的作用[J].中华糖尿病杂志,2004,12：182-186.
[14]曹泽毅.中华妇产科学[M].北京：人民卫生出版社,2003：2178-2181.
[15]曲中玉,石玉华,陈子江.高雄激素血症与多囊卵巢综合征中非酒精性脂肪性肝病的关系[J].生殖与避孕,2011,31(1)：16.[16]吴春凤,刘芸.多囊卵巢综合征卵巢源性高雄激素血症发生机制研究进展[J].临床医学工程,2011,18(1)：147.
[16]Marshll JC.Eagleson CA.Neuine aspests of ovary syondrome [J]. Enderinol & Metab Clin North An,1999,28(2):29-32.
[17]Barba M,Schunemann HJ,Sperati F,et al.The effects of metformin on endogenous androgens and SHBG in women:A systematic review and meta2analysis[J]. Clin Endocrinol,2009,70(5):6612670.
[18]Rosenfield RL,Bordini B.Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity [J]. Brain Res,2010,1364:1862197.
[19]李继俊.妇产科内分泌治疗学[M].第2版.北京：人民军医出版社,2010：294.
[20]宋青,苟文丽.吡格列酮对胰岛素抵抗型多囊卵巢综合征患者脂肪细胞因子的影响[J].西安交通大学学报(医学版),2010,31(2)：228。
[21]乐杰.妇产科学[M].第7版.北京：人民卫生出版社,2011：315.
[22]李继俊.妇产科内分泌治疗学[M].第2版.北京：人民军医出版社,2010：290-291.,
[23]李燕红.导痰种子方联合地屈孕酮治疗多囊卵巢综合征患者黄体功能不全的临床观察[J].四川中医,2012,30(1)：90.
[24]雷彩霞.地屈孕酮用于激素替代疗法的安全性[J].上海医药,2009,30(5)：205.。
[25]Burch D,Bieshuevel E,Smith S,etal Can endome trial protection be inferred from the bleeding pattern on combined cyclical hormone replccement therapy [J]. Maturitas,2000,34(2):155-160.
[26]Adiyono w,Hardian TNF-alpha and L-8profile after dydrogesterone therapy on dysfunctional uterine bleeding patients Third World Congress on Controversies in Obstetrics Gynecology&Infertility [C].2002:11-4.
[27]Campagnoli C,Ambroggio S,etal Differential effects of various progestogenson metabolic risk factors for breast cancer [J].Gynecological Endocrinology,2007, 23(SI):22-31.
[28]杨文艺,杨静,热西但.口服地屈孕酮治疗黄体功能不全型先兆流产疗效观察[J].航空航天医药,2009,20(12)：88-89.
[29]郭建,孙佳明,张志吉等.阿胶化学成分及药理作用研究进展[J].吉林中医药,2013,33(4)：390.
[30]闫红敏.阿胶补血作用的临床观察[J].中医中药,2013,13(11)：301.
[31]颜正华.中药学[M].2版.北京：人民卫生出版社.2006：1009.
[32]梁正林,张晓宁.复方阿胶浆联合促红细胞生成素治疗血透患者贫血疗效观察[J].中华内科杂志,2008,47(5)：735-736.
[33]方红珠.崩漏的中医治疗[J].河北中西医结合杂志,1997,6(6)：958-959.
[34]刘世旺,徐艳霞,徐霞玲等.墨旱莲叶水提取物止血活血初探[J].安徽农业科学,2008,36(31)：13673-13674.
[35]李燕红.导痰种子方联合地屈孕酮治疗多囊卵巢综合征患者黄体功能不全的临床观察[J].四川中医,2012,30(1)：90.。
[36]Dhandapani R.Hypolipidemic activity of Eclipta prostrate L.leaf extract in atherogenic diet induced hyperlipidemic rats[J].Indian J Exp Biol,2007,45(7): 617-619.
[37]尤昭玲,曾润清.多囊卵巢综合征中西医结合研究思路[J].中医药导报,2006,12(1)：13-16.
[38]邓阿黎,周忠明,张亚兵.补肾化痰祛瘀中药对模型大鼠卵巢组织形态学作用的实验研究[J].中国药师,2009,12(2)：143-145.
[39]冯玉昆,陆义芹,孙跃平等.达因-35联合二甲双胍治疗肥胖型PCOS的临床探讨[J].昆明医学院学报,2005,26(1)：50.
[40]邓伟芬,柳倩茹,柳晓春等等.达英-35联合二甲双胍治疗对胰岛素抵抗的多囊卵巢综合征患者子宫内膜胰岛素受体表达的影响[J].中国妇幼保健,2010,25(24)：3488-3491.
[41]余帆.肥胖型多囊卵巢综合征患者血清炎症因子的变化及二甲双胍干预效果的临床研究[J].中国妇幼保健,2011,26(25)：3878-3881.
[42]王完英.二甲双胍对多囊卵巢综合征患者耐氯米芬的作用探讨[J].山西医药杂志,2010,39(8)：715.
[43]赵军招,叶碧绿,林金秀等.二甲双胍在多囊卵巢综合征促排治疗中的应用[J].中华妇产科杂志,2003,38(9)：545-548.
[44]常桂霞,崔建男,吴才凤等.吡格列酮对多囊卵巢综合征伴胰岛素抵抗患者的疗效观察[J].中国妇产科临床杂志,2007,8(3)：191.
[45]辛俊英,辛连芳,白连详.吡格列酮联合克罗米酚促进多囊卵巢综合征排卵效果分析[J].海南医学院学报,2011,17(12)：1679.
[46]候志梅,吴新荣.吡格列酮对2型糖尿病患者C反应蛋白的影响[J].新疆医学大学学报,2009,32(11)：1547-1548.
[47]李仙.吡格列酮联合二甲双胍治疗2型糖尿病59例临床疗效[J].临床合理用药,2013,6(11)：42.
[48]Evans JL, Goldfine ID,Maddux BA,et al.Are oxidative stress activated signaling pathways mediators of insulin resistance and betacell dysfunction. Diabetes,2003, 52(1):1-8.
[49]杨银芬.吡格列酮联合格列齐治疗2型糖尿病的疗效观察[J].中国基层医药,2011,18(2)：248-249.
[50]庄乾竹.多囊卵巢综合征患者的饮食调养[J].食疗食养,2009,1(12)：20-21.
[51]Norman RJ,Wu RJ,Stankiewicz MT.4:Polycystic ovary syndrome[J]. MJA,2004, 180(3):132.
[52]江钟立,刘嘉茵,张勤等.运动队多囊炼成综合征患者的胰岛素抵抗和性激素的影响[J].中国康复医学杂志,2004,19(4)：246-248.
[53]Beloosesky R,Gold R,Almog B,et al.Induction of polycystic ovary by testosterone in immature female rats:Modulation of apoptosis and attenuation of glucose/in sulin ratio[J].Int J Mol Med,2004,14(2):207.
[54]韩美英,岳闽燕.多囊卵巢综合征胰岛素抵抗患者饮食控制及药物干预对近、远期并发症影响的研究[J].中国社区医师,2013,15(4)：71.
[55]Moran LJ,Brinkworh Q Noakes M.Effects of lifestyle modification in polycystic ovarian syndrome [J].Reprod Biomed Online,2006,12(5):569-578.
[56]Sorensen LB,Soe M,Hdkier KH,et al.Effects of increased dietary protein-to-carbohydrate ratios in women with polycystic ovary syndrome[J].Am J Clin Nutr,,2012,95(1):39-48..
[57]黄才英.妈富隆治疗青春期功血42例临床分析[J].临床医学工程,2010,17(10)：68-69.
[58]梁冬莲,林红.黄体酮胶丸与妈富隆治疗围绝经期功血的临床疗效比较[J].当代医学,2012,18(13)：128-129.
[59]Cortinassp,Centenomi,Santiimone BN.Dys-functional uterine bleeding: Bibiographic review[J].Tokopra,1999,58(634):21-30.,
[60]高艳萍,郭华娟.炔雌醇环丙孕酮与雌激素治疗青春期功血的疗效观察[J].贵州医学,2011,35(4)：331-333.
[61]Kaitu'Ulint J,Morison NB,Salamonsen LA.Estrogen is not essenti',d for full endometrial erstoration atferbreakdown:Lessons from a mouse model [J].Endocrinology,2007,148(10):5105-5111.
[62]王如梅,方红.去氧孕烯炔雌醇治疗青春期功血53例分析[J].中国误诊学杂志,2010,10(28)：6981.
[63]孙敏玲.妈富隆和米非司酮治疗围绝经期功能失调性子宫出血的临床疗效对性激素浓度的影响[J].首都医科大学学报,2011,32(3)：417-420.
[64]韩美英,岳闽燕.多囊卵巢综合征胰岛素抵抗患者饮食控制及药物干预对近、远期并发症影响的研究[J].中国社区医师,2013,15(4)：71.
[65]舔秦杰.妈富隆在治疗多囊卵巢综合征患者中的作用[J].中国计划生育学杂志,2011,19(5)：319-320.
[66]王尧尧,郝松莉,候丽辉等.多囊卵巢综合征心血管危险因素研究进展[J].医学研究杂志,2013,42(7)：12-13.
[1]邓选碧.多囊卵巢综合征的两种治疗方法的对比及其中医施治[J].时珍国医国药,2012,23(11)：2918.
[2]李继俊.妇产科内分泌治疗学[M].第2版.北京：人民军医出版社,2010：289.
[3]曹泽毅.中华妇产科学[M].临床版.北京：人民卫生出版社,2010：474.
[4]杨玉,孟军.多囊卵巢综合征伴发子宫内膜增生致病机理的研究进展[J].宁夏医学杂志,2009,31(10)：962.
[5]王利平,王焕焕.补肾丸结合中医体质辨识治疗排卵障碍性不孕症临床观察[J].中医学报,2011,26(7)：877-878.
[6]郭海红,闫星妹,国丽丽.多囊卵巢综合征中医征候分布规律研究[J].河南中医,2013,33(2)：207-208.
[7]李朋粉,孙莹璞,王芳等.多囊卵巢综合征源性人胚胎干细胞系的建立[J].生殖与避孕,2011,31(5)：299.
[8]乐杰.妇产科学[M].第7版.北京：人民卫生出版社,2011：315.
[9]李继俊.妇产科内分泌治疗学[M].第2版.北京：人民军医出版社,2010：290-291.
[10]宋青,苟文丽.吡格列酮对胰岛素抵抗型多囊卵巢综合征患者脂肪细胞因子的影响[J].西安交通大学学报(医学版),2010,31(2)：228.
[11]Karaer A, Cavkaytar S, Mert I, et al. Cardiovascular risk factors in polycystic ovary syndrome. J Obstetrics Gynaecol.2010,30(4):387-92.
[12]Vrbikova J, Fanta M, Cibula D, I et al. Impaired glucose metabolism in women with polycystic ovary syndrome[J]. Gynecol Obstet Invest.2009;68(3):186-190. Epub 2009 Aug 7.
[13]Hu WH, Qiao J, Wang LN, Clinical features of the metabolic syndrome in patients with polycystic ovary syndrome. Beijing Da Xue Xue Bao.2010 Apr 18;42(2):159-63.
[14]吴春凤,刘芸.多囊卵巢综合征卵巢源性高雄激素血症发生机制研究进展[J].临床医学工程,2011,18(1)：147.
[15]曲中玉,石玉华,陈子江.高雄激素血症与多囊卵巢综合征中非酒精性脂肪 性肝病的关系[J].生殖与避孕,2011,31(1)：16.
[16]李继俊.妇产科内分泌治疗学[M].第2版.北京：人民军医出版社,2010：294.
[17]许良智,单丹.多囊卵巢综合征—一种代谢障碍性全身性疾病在卵巢的表现[J].中华妇幼临床医学杂志(电子版),2011,7(5)：407.
[18]Burghen GA,Givens JR,Kitabchi AE.Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease[J].J Clin Endocrinol Metab,1980, 50(1):1132116.
[19]Padmanabhan V. Polycystic ovry syndrome—"A riddle wrapped in a mystery inside an enigma"[J].J Clin Endocrinol Metab,2009,94(6):188321885.
[20]Barba M,Schunemann HJ,Sperati F,et al.The effects of metformin on endogenous androgens and SHBG in women:A systematic review and meta2analysis[J]. Clin Endocrinol,2009,70(5):6612670.
[21]Motta AB.Mechanisms involved in metformin action in the treatment of polycystic ovary syndrome[J].J Curr Pharm Design,2009,15(26):307423077.
[22]Fruzzetti F,Perini D,Lazzarini V,et al.Hyperandrogenemia influences the prevalence of the metabolic syndrome abnormalities in adolescents with the polycystic ovary syndrome [J].Gynecolog Endocrinol,2009,25(5):3352343.
[23]Hendriks ML,Ket JCF,Hompes PGA,et al.why does ovarian surgery in PCOS help?Insight into the endocrine implications of ovarian surgery for ovulation induction in polycystic ovary syndrome[J].Hum Reprod Update,2007,13 (3):2492264.
[24]Rosenfield RL,Bordini B.Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity[J]. Brain Res,2010,1364:1862197.
[25]Ganie MA, Marwaha RK, Aggarwal R, et al.High prevalence of polycystic ovary syndrome characteristics in girls with euthyroid chronic lymphocytic thyroiditis: a case-control study. Eur J Endocrinol.2010 Jun;162(6):1117-22.
[26]史常旭.功能失调性子宫出血的临床类型及诊断[J].中国实用妇科与产科杂志,2004,20(4)：194.
[27]翟晓枝,邓洋.青春期功血后续治疗方法的探讨[J].中国妇幼保健,2011,26：286.
[28]王海艳,王海侠,赵晓荣.妈富隆治疗围绝经期功血的疗效观察[J].中国计划生育学杂志,2011,19(3)：182.
[29]曹泽毅.中华妇产科学[M].临床版.北京：人民卫生出版社,2010：474-475.
[30]朱楣光.功能失调性子宫出血的病因及其病理生理[J].中国实用妇科与产科杂志,2004,20(4)：194-195.
[31]李凤,李放.青春期功能失调性子宫出血患者情绪障碍的临床分析[J].中国校医,2002,16(5)：389.
[32]武红利,康文丽,高伟等.心理因素与青春期女性月经异常关系的研究[J].中国妇幼健康研究,2006,17(2)：73.
[33]陈新贵,肖新梅,黄智聪.缺铁与功能失调性子宫出血的临床分析[J].右江医学,2003,31(4)：339-340.
[34]张惜阴.实用妇产科学.北京：人民卫生出版社,2003：826.
[35]A Daniilidis, K Dinas.Long term health consequences of polycystic ovarian syndrome. J a review Hippokratia.2009,13(2):90-92.
[36]Moreira S, Soares E, Tomaz G, et al. Polycystic ovary syndrome:a psychosocial approach. J Acta Med Port,2010,23(2):237-42.
[37]Tracy l,AnnMD,Brown JlMD MHS:polycystic ovary syndrome:Diagno2sis and Treatment [J].The American Journal of medicine,2007,120(1):128-132.
[38]Teede H,Deeks A,Moran L.Polycystic ovary syndrome:a complex condition with psychological,reproductive and metabolic manifestations that impacts on health across the lifespan[J].BMCMed,2010,58:41.
[39]Legro RS.A 272year2old woman with a diagnosis of polycystic ovary syndrome [J].JAMA,2007,297(5):5092519.
[40]Kaaja RJ,Poyhonen2Alho Mk.Insulin resistance and sympathetic overactivity in women[J].J Hypertens,2006,24(1):1312141.
[41]Zborowski JV,Talbott EO,Cauley JA.Polycystic ovary syndrome,androgen excess,and the impact on bone [J].Obstet Gynecol Clin North Am,2001,28(1): 1352151.
[42]Janssen OE,Mehlmauer N,Hahn S,et al.High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome[J].Eur J Endocrinol,2004, 150(3):3632369.
[43]许良智,单丹.多囊卵巢综合征—一种代谢障碍性全身性疾病在卵巢的表现[J].中华妇幼临床医学杂志(电子版),2011,7(5)：408.
[44]乐杰.妇产科学[M].第7版.北京：人民卫生出版社,2011：302.
[45]谢梦,周毓青,林金芳.多囊卵巢综合征卵巢超声影像学特征及其与内分泌代谢异常的相关性分析[J].中国实用妇科与产科杂志,2008,24(9)：676.
[46]曹泽毅.中华妇产科学[M].临床版.北京：人民卫生出版社,2010：503.
[47]Vibikova J,Hainer V.Obesity and polycystic ovary syndrome [J].J Obes Facts, 2009,2(1):26-35.
[48]Teede H,Deeks A,Moran L.Polycystic ovary syndrome:a complex condition with psychological,reproductive and metabolic manifestations that impacts on health across the lifespan[J]BMC,2010,8(1):41.
[49]Gambineri A,Patton L,Vaccina A,et al.Treatment with flutamide metformin and their combination added to a hypocaloric diet in over weighe-obese women with polycystic ovary syndrome:a randomi zed.12-month,placebo-controlled study[J]. J Clin Endocrinol Metab,2006,91(10):3970-3980.
[50]Palomba S,Falbo A,Giallauria F,et al.Six weeks of structured exercise training ang hypocaloric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome:a randomized controlled trial[J].Hum Reprod.2010,25(11):2783-2791.
[51]Otta CF,Woor M,Iraci GS,et al.Clinical,metabolic,and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome:a randomized,double-blind,and placebo control trial[J].Gynecol Endocrinol,2010 26(3):173-178.
[52]Masharani U,Gjerde C,Evans JL,et al.Effects of controlled-release alpha lipoic acid in lean,nondiabetic patients with polycystic ovary syndrome[J].J Diabetes Sci Technol.2010,4(2):359-364.
[53]夏和霞.饮食因素在多囊卵巢综合征治疗中的作用[J].国际妇产科学杂志,2008,35(3)：217.
[54]Hoeger K,Davidson K,Kochman L,et al.The impact of metformin,oral contraceptives,and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized,placebo-controlled clinical trials[J].J Clin Endocrinol Metab.2008,93(11):4299-4306.
[55]Falsetti L,Gambera A,Tisi GI.Efficial of the combination ethinyl oestradiol and cyproterone acetate on endocrine,clinical and ultrasonographic profile in polycystic ovarian syndromel[J].Human Reprod,2001,16(1):36-42.
[56]夏和霞,张炜.口服避孕药醋酸环丙孕酮炔雌醇片治疗多囊卵巢综合征[J].上海医药,2011,32(3)：115-116.
[57]Lobo.Clomiphene and dexamethason in women unresponsive to clomiphene alone[J].Obster Gynecol,1982,60(3):497-501.
[58]黄佩宁.地塞米松提高多囊卵巢综合征排卵及妊娠率的分析[J].中国社区医师(医学专业),2011,13(05)：71.
[59]孙梅,陈子江.多囊卵巢综合征的治疗及其卵巢功能保护[J].中国妇产科临床杂志,2010,11(5)：71.
[60]刘晓霞,周惠芳.多囊卵巢综合征所致不孕的中西医治疗概况[J].辽宁中医药大学学报,2011,13(5)：265.
[61]Legro RS,Barnhart HX,Schaff WD,et al.Clomiphene,metformin,or both for infertility in the polycystic ovary syndrome[J].N Engl J Med.2007,365 (6): 551-566.
[62]邹品洁.二甲双胍联合氯米芬治疗多囊卵巢综合症促排卵效果观察[J].中国医学工程,2009,17(1)：72.
[63]俞飞.达英-35氯米芬治疗多囊卵巢综合征临床观察[J].基层医学论坛,2011,15：1064.
[64]王泽华.妇产科治疗学[M].第1版.北京：人民卫生出版社,2009：723.
[65]Abu Hashim H,Shokeir T,Badawy A.Letrozole versus combined metformin and clomiphene crtrate vulation induction in clomiphene-resistant women with polycystic ovary syndrome:a randomized controlled trial[J].Fertil Steril.2010, 94(4):1405-1409.
[66]Tiboni GM,Marotta F,Rossi C,et al.Effects of the aromatase inhibitor letrozole on in utero development in rats[J].Hum Reprod,2008,23:1719-1723
[67]何东红,蒋凤艳.来曲唑用于多囊卵巢综合征患者诱导排卵的系统评价[J].现代妇产科进展,2011,20(9)：701.
[68]魏巍,周莉莉,孙壮状等.复方环丙孕酮联合胰岛素增敏剂对非肥胖多囊卵巢综合征伴有胰岛素抵抗患者治疗效果的观察[J].中国优生与遗传学,2009,17(8)：59.
[69]Cheang KI, Huszar JM, Best AM, et al. Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome[J]. Diab Vasc Dis Res. 2009 Apr; 6(2):110-9.
[70]Palomba S,Orio F Jr,Falbo A, et al. Prospective parallel randomized, double-blind,double-dummy controlled clinical trial comparing clomiphene citrate and metform in as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome[J].Clin Endocrinol Metab,2005,90:4068-4074.
[71]Checa MA,Requena A,Salvador C, et al. Insulin-sensitizing agents:use in p-regnancy and as therapy in polycystic ovary syndrome[J].Hum Reprod Update,2005,11(4):375-390.
[72]Glintborg D,Hojlund K,Andersen NR,et al.Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment[J].J Clin Endocrinol Metab.2008,93(9):3618-3626.
[73]Elkind-Hirsch KE.Thiazolidinediones for the Therapeutic Management of Polycystic Ovary Syndrome:Impact on Metabolic and Rep roductive Abnormalitie Treat Endocrinol[J].Treat Endocrinol,2006,5(3):171-187.
[74]Lemay A, Dodin S, Turcot L, et al. Rosiglitazone and ethinyl estradiol/cyp-roterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance[J].Hum Reprod, 2006,21 (1):121-128.
[75]Rouzi AA,ArdawiMS.A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metform in and clom-iphenecitrate in women with clomiphene citrate-resistant polycystic ovary syndrome[J]. Fertil Steril,2006,85(2):428-435.
[76]Steven EN issen,Kathy Wolski.Effect of Rosiglitazone on the R isk of Myocardial Infarction and Death from Cardiovascular Causes[J].NEngl J Med, 2007,356:2457-2471.
[77]Philip D,D Phil, Henning Beck-Nielsen, et al. Rosiglitazone E2 valuated for Cardiovascular Outcomes-An Interim Analysis[J].NEngl J Med,2007,357:937-940.
[78]Tang WH, Maroo A.PPAR gamma agonists:safety issues in heart failure[J].D-iabetes Obes Metab,2007,9(4):447-454.
[79]张梅莹,狄文.手术治疗多囊卵巢综合征的评估[J].中国妇幼健康研究,2007,18(1)：51-53.
[80]洪岭,梁俊华,童晓文.多囊卵巢综合征手术治疗进展[J].中国实用妇科与产科杂志,2009,25(4)：312.
[81]黄丽丽,杨冬梓.重视多囊卵巢综合征对辅助生殖技术结局的影响[J].中国妇产科临床杂志,2008,9(5)：323.
[82]曹泽毅.中华妇产科学[M].临床版.北京：人民卫生出版社,2010：507.
[83]祁友莲.功能失调性子宫出血的性激素治疗[J].中国实用医药,2011,6(11)：257-258.
[84]舔秦杰.妈富隆在治疗多囊卵巢综合征患者中的作用[J].中国计划生育学杂志,2011,19(5)：319-320.
[85]徐静,康丽红.曼月乐在功能失调性子宫出血中的应用[J].中国医药导报,2011,8(8)：44.
[86]杨玉,孟军.多囊卵巢综合征伴发子宫内膜增生致病机理的研究进展[J].宁夏医学杂志,2009,31(10)：962.
[2]刘敏如、谭万信.中医妇产科学[M].北京：人民卫生出版社,2001：307.
[3]王永炎.完善中医辨证方法体系的建议[J].中医杂志,2004,45(10)：729-731.
[4]中医药管理局.《中华人民共和国中医药行业标准·中医病证诊断疗效标准》[M].北京,1994.
[5]中华人民共和国卫生部.《中药新药临床研究指导原则》[M].北京,1993.
[6]张玉珍.《中医妇科学》[M].北京：中国中医药出版社,2007.
[7]中国中西医结合研究会第一次全国活血化瘀学术会议：血瘀证诊断试行标准.中西医结合杂志,1983：3(3)：封二.
[8]王桂敏,郑淑荣.女性生殖器官血管研究现状.生殖与避孕,1996,1(1)：3-6.
[9]胡淑芳.经阴道彩色多普勒观测卵巢动脉PI、RI值和卵泡发育的关系.临床超声医学杂志,1995,1(4)：215-218.
[10]陈可冀,张子南,梁子均等.血瘀证与活血化瘀研究.上海：上海科学技术出版社,1990.368.
[11]郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002.
[12]罗璐.功能失调性子宫出血研究新进展[M].国外医学妇产科学分册,2002,29(2)：88.
[13]邢小燕,杨文英,杨兆军.胰岛素抵抗指数在不同糖耐量人群中诊断代谢综合征的作用[J].中华糖尿病杂志,2004,12：182-186.
[14]曹泽毅.中华妇产科学[M].北京：人民卫生出版社,2003：2178-2181.
[15]曲中玉,石玉华,陈子江.高雄激素血症与多囊卵巢综合征中非酒精性脂肪性肝病的关系[J].生殖与避孕,2011,31(1)：16.[16]吴春凤,刘芸.多囊卵巢综合征卵巢源性高雄激素血症发生机制研究进展[J].临床医学工程,2011,18(1)：147.
[16]Marshll JC.Eagleson CA.Neuine aspests of ovary syondrome [J]. Enderinol & Metab Clin North An,1999,28(2):29-32.
[17]Barba M,Schunemann HJ,Sperati F,et al.The effects of metformin on endogenous androgens and SHBG in women:A systematic review and meta2analysis[J]. Clin Endocrinol,2009,70(5):6612670.
[18]Rosenfield RL,Bordini B.Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity [J]. Brain Res,2010,1364:1862197.
[19]李继俊.妇产科内分泌治疗学[M].第2版.北京：人民军医出版社,2010：294.
[20]宋青,苟文丽.吡格列酮对胰岛素抵抗型多囊卵巢综合征患者脂肪细胞因子的影响[J].西安交通大学学报(医学版),2010,31(2)：228。
[21]乐杰.妇产科学[M].第7版.北京：人民卫生出版社,2011：315.
[22]李继俊.妇产科内分泌治疗学[M].第2版.北京：人民军医出版社,2010：290-291.,
[23]李燕红.导痰种子方联合地屈孕酮治疗多囊卵巢综合征患者黄体功能不全的临床观察[J].四川中医,2012,30(1)：90.
[24]雷彩霞.地屈孕酮用于激素替代疗法的安全性[J].上海医药,2009,30(5)：205.。
[25]Burch D,Bieshuevel E,Smith S,etal Can endome trial protection be inferred from the bleeding pattern on combined cyclical hormone replccement therapy [J]. Maturitas,2000,34(2):155-160.
[26]Adiyono w,Hardian TNF-alpha and L-8profile after dydrogesterone therapy on dysfunctional uterine bleeding patients Third World Congress on Controversies in Obstetrics Gynecology&Infertility [C].2002:11-4.
[27]Campagnoli C,Ambroggio S,etal Differential effects of various progestogenson metabolic risk factors for breast cancer [J].Gynecological Endocrinology,2007, 23(SI):22-31.
[28]杨文艺,杨静,热西但.口服地屈孕酮治疗黄体功能不全型先兆流产疗效观察[J].航空航天医药,2009,20(12)：88-89.
[29]郭建,孙佳明,张志吉等.阿胶化学成分及药理作用研究进展[J].吉林中医药,2013,33(4)：390.
[30]闫红敏.阿胶补血作用的临床观察[J].中医中药,2013,13(11)：301.
[31]颜正华.中药学[M].2版.北京：人民卫生出版社.2006：1009.
[32]梁正林,张晓宁.复方阿胶浆联合促红细胞生成素治疗血透患者贫血疗效观察[J].中华内科杂志,2008,47(5)：735-736.
[33]方红珠.崩漏的中医治疗[J].河北中西医结合杂志,1997,6(6)：958-959.
[34]刘世旺,徐艳霞,徐霞玲等.墨旱莲叶水提取物止血活血初探[J].安徽农业科学,2008,36(31)：13673-13674.
[35]李燕红.导痰种子方联合地屈孕酮治疗多囊卵巢综合征患者黄体功能不全的临床观察[J].四川中医,2012,30(1)：90.。
[36]Dhandapani R.Hypolipidemic activity of Eclipta prostrate L.leaf extract in atherogenic diet induced hyperlipidemic rats[J].Indian J Exp Biol,2007,45(7): 617-619.
[37]尤昭玲,曾润清.多囊卵巢综合征中西医结合研究思路[J].中医药导报,2006,12(1)：13-16.
[38]邓阿黎,周忠明,张亚兵.补肾化痰祛瘀中药对模型大鼠卵巢组织形态学作用的实验研究[J].中国药师,2009,12(2)：143-145.
[39]冯玉昆,陆义芹,孙跃平等.达因-35联合二甲双胍治疗肥胖型PCOS的临床探讨[J].昆明医学院学报,2005,26(1)：50.
[40]邓伟芬,柳倩茹,柳晓春等等.达英-35联合二甲双胍治疗对胰岛素抵抗的多囊卵巢综合征患者子宫内膜胰岛素受体表达的影响[J].中国妇幼保健,2010,25(24)：3488-3491.
[41]余帆.肥胖型多囊卵巢综合征患者血清炎症因子的变化及二甲双胍干预效果的临床研究[J].中国妇幼保健,2011,26(25)：3878-3881.
[42]王完英.二甲双胍对多囊卵巢综合征患者耐氯米芬的作用探讨[J].山西医药杂志,2010,39(8)：715.
[43]赵军招,叶碧绿,林金秀等.二甲双胍在多囊卵巢综合征促排治疗中的应用[J].中华妇产科杂志,2003,38(9)：545-548.
[44]常桂霞,崔建男,吴才凤等.吡格列酮对多囊卵巢综合征伴胰岛素抵抗患者的疗效观察[J].中国妇产科临床杂志,2007,8(3)：191.
[45]辛俊英,辛连芳,白连详.吡格列酮联合克罗米酚促进多囊卵巢综合征排卵效果分析[J].海南医学院学报,2011,17(12)：1679.
[46]候志梅,吴新荣.吡格列酮对2型糖尿病患者C反应蛋白的影响[J].新疆医学大学学报,2009,32(11)：1547-1548.
[47]李仙.吡格列酮联合二甲双胍治疗2型糖尿病59例临床疗效[J].临床合理用药,2013,6(11)：42.
[48]Evans JL, Goldfine ID,Maddux BA,et al.Are oxidative stress activated signaling pathways mediators of insulin resistance and betacell dysfunction. Diabetes,2003, 52(1):1-8.
[49]杨银芬.吡格列酮联合格列齐治疗2型糖尿病的疗效观察[J].中国基层医药,2011,18(2)：248-249.
[50]庄乾竹.多囊卵巢综合征患者的饮食调养[J].食疗食养,2009,1(12)：20-21.
[51]Norman RJ,Wu RJ,Stankiewicz MT.4:Polycystic ovary syndrome[J]. MJA,2004, 180(3):132.
[52]江钟立,刘嘉茵,张勤等.运动队多囊炼成综合征患者的胰岛素抵抗和性激素的影响[J].中国康复医学杂志,2004,19(4)：246-248.
[53]Beloosesky R,Gold R,Almog B,et al.Induction of polycystic ovary by testosterone in immature female rats:Modulation of apoptosis and attenuation of glucose/in sulin ratio[J].Int J Mol Med,2004,14(2):207.
[54]韩美英,岳闽燕.多囊卵巢综合征胰岛素抵抗患者饮食控制及药物干预对近、远期并发症影响的研究[J].中国社区医师,2013,15(4)：71.
[55]Moran LJ,Brinkworh Q Noakes M.Effects of lifestyle modification in polycystic ovarian syndrome [J].Reprod Biomed Online,2006,12(5):569-578.
[56]Sorensen LB,Soe M,Hdkier KH,et al.Effects of increased dietary protein-to-carbohydrate ratios in women with polycystic ovary syndrome[J].Am J Clin Nutr,,2012,95(1):39-48..
[57]黄才英.妈富隆治疗青春期功血42例临床分析[J].临床医学工程,2010,17(10)：68-69.
[58]梁冬莲,林红.黄体酮胶丸与妈富隆治疗围绝经期功血的临床疗效比较[J].当代医学,2012,18(13)：128-129.
[59]Cortinassp,Centenomi,Santiimone BN.Dys-functional uterine bleeding: Bibiographic review[J].Tokopra,1999,58(634):21-30.,
[60]高艳萍,郭华娟.炔雌醇环丙孕酮与雌激素治疗青春期功血的疗效观察[J].贵州医学,2011,35(4)：331-333.
[61]Kaitu'Ulint J,Morison NB,Salamonsen LA.Estrogen is not essenti',d for full endometrial erstoration atferbreakdown:Lessons from a mouse model [J].Endocrinology,2007,148(10):5105-5111.
[62]王如梅,方红.去氧孕烯炔雌醇治疗青春期功血53例分析[J].中国误诊学杂志,2010,10(28)：6981.
[63]孙敏玲.妈富隆和米非司酮治疗围绝经期功能失调性子宫出血的临床疗效对性激素浓度的影响[J].首都医科大学学报,2011,32(3)：417-420.
[64]韩美英,岳闽燕.多囊卵巢综合征胰岛素抵抗患者饮食控制及药物干预对近、远期并发症影响的研究[J].中国社区医师,2013,15(4)：71.
[65]舔秦杰.妈富隆在治疗多囊卵巢综合征患者中的作用[J].中国计划生育学杂志,2011,19(5)：319-320.
[66]王尧尧,郝松莉,候丽辉等.多囊卵巢综合征心血管危险因素研究进展[J].医学研究杂志,2013,42(7)：12-13.
[1]邓选碧.多囊卵巢综合征的两种治疗方法的对比及其中医施治[J].时珍国医国药,2012,23(11)：2918.
[2]李继俊.妇产科内分泌治疗学[M].第2版.北京：人民军医出版社,2010：289.
[3]曹泽毅.中华妇产科学[M].临床版.北京：人民卫生出版社,2010：474.
[4]杨玉,孟军.多囊卵巢综合征伴发子宫内膜增生致病机理的研究进展[J].宁夏医学杂志,2009,31(10)：962.
[5]王利平,王焕焕.补肾丸结合中医体质辨识治疗排卵障碍性不孕症临床观察[J].中医学报,2011,26(7)：877-878.
[6]郭海红,闫星妹,国丽丽.多囊卵巢综合征中医征候分布规律研究[J].河南中医,2013,33(2)：207-208.
[7]李朋粉,孙莹璞,王芳等.多囊卵巢综合征源性人胚胎干细胞系的建立[J].生殖与避孕,2011,31(5)：299.
[8]乐杰.妇产科学[M].第7版.北京：人民卫生出版社,2011：315.
[9]李继俊.妇产科内分泌治疗学[M].第2版.北京：人民军医出版社,2010：290-291.
[10]宋青,苟文丽.吡格列酮对胰岛素抵抗型多囊卵巢综合征患者脂肪细胞因子的影响[J].西安交通大学学报(医学版),2010,31(2)：228.
[11]Karaer A, Cavkaytar S, Mert I, et al. Cardiovascular risk factors in polycystic ovary syndrome. J Obstetrics Gynaecol.2010,30(4):387-92.
[12]Vrbikova J, Fanta M, Cibula D, I et al. Impaired glucose metabolism in women with polycystic ovary syndrome[J]. Gynecol Obstet Invest.2009;68(3):186-190. Epub 2009 Aug 7.
[13]Hu WH, Qiao J, Wang LN, Clinical features of the metabolic syndrome in patients with polycystic ovary syndrome. Beijing Da Xue Xue Bao.2010 Apr 18;42(2):159-63.
[14]吴春凤,刘芸.多囊卵巢综合征卵巢源性高雄激素血症发生机制研究进展[J].临床医学工程,2011,18(1)：147.
[15]曲中玉,石玉华,陈子江.高雄激素血症与多囊卵巢综合征中非酒精性脂肪 性肝病的关系[J].生殖与避孕,2011,31(1)：16.
[16]李继俊.妇产科内分泌治疗学[M].第2版.北京：人民军医出版社,2010：294.
[17]许良智,单丹.多囊卵巢综合征—一种代谢障碍性全身性疾病在卵巢的表现[J].中华妇幼临床医学杂志(电子版),2011,7(5)：407.
[18]Burghen GA,Givens JR,Kitabchi AE.Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease[J].J Clin Endocrinol Metab,1980, 50(1):1132116.
[19]Padmanabhan V. Polycystic ovry syndrome—"A riddle wrapped in a mystery inside an enigma"[J].J Clin Endocrinol Metab,2009,94(6):188321885.
[20]Barba M,Schunemann HJ,Sperati F,et al.The effects of metformin on endogenous androgens and SHBG in women:A systematic review and meta2analysis[J]. Clin Endocrinol,2009,70(5):6612670.
[21]Motta AB.Mechanisms involved in metformin action in the treatment of polycystic ovary syndrome[J].J Curr Pharm Design,2009,15(26):307423077.
[22]Fruzzetti F,Perini D,Lazzarini V,et al.Hyperandrogenemia influences the prevalence of the metabolic syndrome abnormalities in adolescents with the polycystic ovary syndrome [J].Gynecolog Endocrinol,2009,25(5):3352343.
[23]Hendriks ML,Ket JCF,Hompes PGA,et al.why does ovarian surgery in PCOS help?Insight into the endocrine implications of ovarian surgery for ovulation induction in polycystic ovary syndrome[J].Hum Reprod Update,2007,13 (3):2492264.
[24]Rosenfield RL,Bordini B.Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity[J]. Brain Res,2010,1364:1862197.
[25]Ganie MA, Marwaha RK, Aggarwal R, et al.High prevalence of polycystic ovary syndrome characteristics in girls with euthyroid chronic lymphocytic thyroiditis: a case-control study. Eur J Endocrinol.2010 Jun;162(6):1117-22.
[26]史常旭.功能失调性子宫出血的临床类型及诊断[J].中国实用妇科与产科杂志,2004,20(4)：194.
[27]翟晓枝,邓洋.青春期功血后续治疗方法的探讨[J].中国妇幼保健,2011,26：286.
[28]王海艳,王海侠,赵晓荣.妈富隆治疗围绝经期功血的疗效观察[J].中国计划生育学杂志,2011,19(3)：182.
[29]曹泽毅.中华妇产科学[M].临床版.北京：人民卫生出版社,2010：474-475.
[30]朱楣光.功能失调性子宫出血的病因及其病理生理[J].中国实用妇科与产科杂志,2004,20(4)：194-195.
[31]李凤,李放.青春期功能失调性子宫出血患者情绪障碍的临床分析[J].中国校医,2002,16(5)：389.
[32]武红利,康文丽,高伟等.心理因素与青春期女性月经异常关系的研究[J].中国妇幼健康研究,2006,17(2)：73.
[33]陈新贵,肖新梅,黄智聪.缺铁与功能失调性子宫出血的临床分析[J].右江医学,2003,31(4)：339-340.
[34]张惜阴.实用妇产科学.北京：人民卫生出版社,2003：826.
[35]A Daniilidis, K Dinas.Long term health consequences of polycystic ovarian syndrome. J a review Hippokratia.2009,13(2):90-92.
[36]Moreira S, Soares E, Tomaz G, et al. Polycystic ovary syndrome:a psychosocial approach. J Acta Med Port,2010,23(2):237-42.
[37]Tracy l,AnnMD,Brown JlMD MHS:polycystic ovary syndrome:Diagno2sis and Treatment [J].The American Journal of medicine,2007,120(1):128-132.
[38]Teede H,Deeks A,Moran L.Polycystic ovary syndrome:a complex condition with psychological,reproductive and metabolic manifestations that impacts on health across the lifespan[J].BMCMed,2010,58:41.
[39]Legro RS.A 272year2old woman with a diagnosis of polycystic ovary syndrome [J].JAMA,2007,297(5):5092519.
[40]Kaaja RJ,Poyhonen2Alho Mk.Insulin resistance and sympathetic overactivity in women[J].J Hypertens,2006,24(1):1312141.
[41]Zborowski JV,Talbott EO,Cauley JA.Polycystic ovary syndrome,androgen excess,and the impact on bone [J].Obstet Gynecol Clin North Am,2001,28(1): 1352151.
[42]Janssen OE,Mehlmauer N,Hahn S,et al.High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome[J].Eur J Endocrinol,2004, 150(3):3632369.
[43]许良智,单丹.多囊卵巢综合征—一种代谢障碍性全身性疾病在卵巢的表现[J].中华妇幼临床医学杂志(电子版),2011,7(5)：408.
[44]乐杰.妇产科学[M].第7版.北京：人民卫生出版社,2011：302.
[45]谢梦,周毓青,林金芳.多囊卵巢综合征卵巢超声影像学特征及其与内分泌代谢异常的相关性分析[J].中国实用妇科与产科杂志,2008,24(9)：676.
[46]曹泽毅.中华妇产科学[M].临床版.北京：人民卫生出版社,2010：503.
[47]Vibikova J,Hainer V.Obesity and polycystic ovary syndrome [J].J Obes Facts, 2009,2(1):26-35.
[48]Teede H,Deeks A,Moran L.Polycystic ovary syndrome:a complex condition with psychological,reproductive and metabolic manifestations that impacts on health across the lifespan[J]BMC,2010,8(1):41.
[49]Gambineri A,Patton L,Vaccina A,et al.Treatment with flutamide metformin and their combination added to a hypocaloric diet in over weighe-obese women with polycystic ovary syndrome:a randomi zed.12-month,placebo-controlled study[J]. J Clin Endocrinol Metab,2006,91(10):3970-3980.
[50]Palomba S,Falbo A,Giallauria F,et al.Six weeks of structured exercise training ang hypocaloric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome:a randomized controlled trial[J].Hum Reprod.2010,25(11):2783-2791.
[51]Otta CF,Woor M,Iraci GS,et al.Clinical,metabolic,and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome:a randomized,double-blind,and placebo control trial[J].Gynecol Endocrinol,2010 26(3):173-178.
[52]Masharani U,Gjerde C,Evans JL,et al.Effects of controlled-release alpha lipoic acid in lean,nondiabetic patients with polycystic ovary syndrome[J].J Diabetes Sci Technol.2010,4(2):359-364.
[53]夏和霞.饮食因素在多囊卵巢综合征治疗中的作用[J].国际妇产科学杂志,2008,35(3)：217.
[54]Hoeger K,Davidson K,Kochman L,et al.The impact of metformin,oral contraceptives,and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized,placebo-controlled clinical trials[J].J Clin Endocrinol Metab.2008,93(11):4299-4306.
[55]Falsetti L,Gambera A,Tisi GI.Efficial of the combination ethinyl oestradiol and cyproterone acetate on endocrine,clinical and ultrasonographic profile in polycystic ovarian syndromel[J].Human Reprod,2001,16(1):36-42.
[56]夏和霞,张炜.口服避孕药醋酸环丙孕酮炔雌醇片治疗多囊卵巢综合征[J].上海医药,2011,32(3)：115-116.
[57]Lobo.Clomiphene and dexamethason in women unresponsive to clomiphene alone[J].Obster Gynecol,1982,60(3):497-501.
[58]黄佩宁.地塞米松提高多囊卵巢综合征排卵及妊娠率的分析[J].中国社区医师(医学专业),2011,13(05)：71.
[59]孙梅,陈子江.多囊卵巢综合征的治疗及其卵巢功能保护[J].中国妇产科临床杂志,2010,11(5)：71.
[60]刘晓霞,周惠芳.多囊卵巢综合征所致不孕的中西医治疗概况[J].辽宁中医药大学学报,2011,13(5)：265.
[61]Legro RS,Barnhart HX,Schaff WD,et al.Clomiphene,metformin,or both for infertility in the polycystic ovary syndrome[J].N Engl J Med.2007,365 (6): 551-566.
[62]邹品洁.二甲双胍联合氯米芬治疗多囊卵巢综合症促排卵效果观察[J].中国医学工程,2009,17(1)：72.
[63]俞飞.达英-35氯米芬治疗多囊卵巢综合征临床观察[J].基层医学论坛,2011,15：1064.
[64]王泽华.妇产科治疗学[M].第1版.北京：人民卫生出版社,2009：723.
[65]Abu Hashim H,Shokeir T,Badawy A.Letrozole versus combined metformin and clomiphene crtrate vulation induction in clomiphene-resistant women with polycystic ovary syndrome:a randomized controlled trial[J].Fertil Steril.2010, 94(4):1405-1409.
[66]Tiboni GM,Marotta F,Rossi C,et al.Effects of the aromatase inhibitor letrozole on in utero development in rats[J].Hum Reprod,2008,23:1719-1723
[67]何东红,蒋凤艳.来曲唑用于多囊卵巢综合征患者诱导排卵的系统评价[J].现代妇产科进展,2011,20(9)：701.
[68]魏巍,周莉莉,孙壮状等.复方环丙孕酮联合胰岛素增敏剂对非肥胖多囊卵巢综合征伴有胰岛素抵抗患者治疗效果的观察[J].中国优生与遗传学,2009,17(8)：59.
[69]Cheang KI, Huszar JM, Best AM, et al. Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome[J]. Diab Vasc Dis Res. 2009 Apr; 6(2):110-9.
[70]Palomba S,Orio F Jr,Falbo A, et al. Prospective parallel randomized, double-blind,double-dummy controlled clinical trial comparing clomiphene citrate and metform in as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome[J].Clin Endocrinol Metab,2005,90:4068-4074.
[71]Checa MA,Requena A,Salvador C, et al. Insulin-sensitizing agents:use in p-regnancy and as therapy in polycystic ovary syndrome[J].Hum Reprod Update,2005,11(4):375-390.
[72]Glintborg D,Hojlund K,Andersen NR,et al.Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment[J].J Clin Endocrinol Metab.2008,93(9):3618-3626.
[73]Elkind-Hirsch KE.Thiazolidinediones for the Therapeutic Management of Polycystic Ovary Syndrome:Impact on Metabolic and Rep roductive Abnormalitie Treat Endocrinol[J].Treat Endocrinol,2006,5(3):171-187.
[74]Lemay A, Dodin S, Turcot L, et al. Rosiglitazone and ethinyl estradiol/cyp-roterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance[J].Hum Reprod, 2006,21 (1):121-128.
[75]Rouzi AA,ArdawiMS.A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metform in and clom-iphenecitrate in women with clomiphene citrate-resistant polycystic ovary syndrome[J]. Fertil Steril,2006,85(2):428-435.
[76]Steven EN issen,Kathy Wolski.Effect of Rosiglitazone on the R isk of Myocardial Infarction and Death from Cardiovascular Causes[J].NEngl J Med, 2007,356:2457-2471.
[77]Philip D,D Phil, Henning Beck-Nielsen, et al. Rosiglitazone E2 valuated for Cardiovascular Outcomes-An Interim Analysis[J].NEngl J Med,2007,357:937-940.
[78]Tang WH, Maroo A.PPAR gamma agonists:safety issues in heart failure[J].D-iabetes Obes Metab,2007,9(4):447-454.
[79]张梅莹,狄文.手术治疗多囊卵巢综合征的评估[J].中国妇幼健康研究,2007,18(1)：51-53.
[80]洪岭,梁俊华,童晓文.多囊卵巢综合征手术治疗进展[J].中国实用妇科与产科杂志,2009,25(4)：312.
[81]黄丽丽,杨冬梓.重视多囊卵巢综合征对辅助生殖技术结局的影响[J].中国妇产科临床杂志,2008,9(5)：323.
[82]曹泽毅.中华妇产科学[M].临床版.北京：人民卫生出版社,2010：507.
[83]祁友莲.功能失调性子宫出血的性激素治疗[J].中国实用医药,2011,6(11)：257-258.
[84]舔秦杰.妈富隆在治疗多囊卵巢综合征患者中的作用[J].中国计划生育学杂志,2011,19(5)：319-320.
[85]徐静,康丽红.曼月乐在功能失调性子宫出血中的应用[J].中国医药导报,2011,8(8)：44.
[86]杨玉,孟军.多囊卵巢综合征伴发子宫内膜增生致病机理的研究进展[J].宁夏医学杂志,2009,31(10)：962.